Role of NADPH oxidase in formation and function of multinucleated giant cells

Journal of Innate Immunity

Volumn 1, Issue 6, 2009, Pages 509-526

  Quinn, Mark T ^a   Schepetkin, Igor A ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

Giant cell; Granuloma; Inflammation; Innate immunity; Macrophage fusion; NADPH oxidase; Osteoclast; Reactive oxygen species; Superoxide anion

Indexed keywords

BETA INTEGRIN; CALPAIN 1; CD200 ANTIGEN; CD36 ANTIGEN; CD47 ANTIGEN; COLONY STIMULATING FACTOR 1; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; MEMBRANE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PEPTIDOGLYCAN; PROTEIN C FOS; PURINERGIC P2X7 RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SIGNAL REGULATORY PROTEIN ALPHA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR PU 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CALCIUM SIGNALING; CELL FUNCTION; CELL FUSION; FOREIGN BODY; GIANT CELL; GIANT CELL ARTERITIS; HUMAN; INFLAMMATION; INTRACELLULAR BACTERIUM; LANGHANS GIANT CELL; MACROPHAGE; OSTEOCLAST; OSTEOCLASTOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATIC DISEASE; SARCOIDOSIS; TISSUE REPAIR;

ANIMALS; GIANT CELLS; HUMANS; MACROPHAGES; NADPH OXIDASE; REACTIVE OXYGEN SPECIES;

EID: 70449627706     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000228158     Document Type: Review

References (174)

1. Helming L, Gordon S: The molecular basis of macrophage fusion. Immunobiology 2007; 212: 785-793.
2. Vignery A: Macrophage fusion: Molecular mechanisms. Methods Mol Biol 2008; 475: 149-161.
3. Langhans T: Über Riesenzellen mit wandständigen Kernen in Tuberkeln und die fibröse Form des Tuberkels. Virchows Arch Pathol Anat 1868; 382-404.
4. Väänänen HK, Zhao H, Mulari M, Halleen JM: The cell biology of osteoclast function. J Cell Sci 2000; 113: 377-381.
5. Ruibal-Ares B, Riera NE, de Bracco MM: Macrophages, multinucleated giant cells, and apoptosis in HIV+ patients and normal blood donors. Clin Immunol Immunopathol 1997; 82: 102-116.
6. Brodbeck, WG, Anderson JM: Giant cell formation and function. Curr Opin Hematol 2009; 16: 53-57.
7. Aterman K, Remmele, W, Smith M: Karl Touton and his 'xanthelasmatic giant cell.' A selective review of multinucleated giant cells. Am J Dermatopathol 1988; 10: 257-269.
8. Dayan D, Buchner A, Garlick J: Touton-like giant cells in periapical granulomas. J Endod 1989; 15: 210-211.
9. Kodama H, Akiyama H, Nagao Y, Akagi O, Nohara N: Persistence of foam cells in rabbit xanthoma after normalization of serum cholesterol level. Arch Dermatol Res 1988; 280: 108-113. (Pubitemid 18094687)
10. Consolaro A, Sant'Ana E, Lawall MA, Consolaro MF, Bacchi CE: Gingival juvenile xanthogranuloma in an adult patient: case report with immunohistochemical analysis and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: 246-252.
11. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA: The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 1996; 137: 4058-4060.
12. Vignery A: Osteoclasts and giant cells: Macrophage- macrophage fusion mechanism. Int J Exp Pathol 2000; 81: 291-304.
13. Zheng MH, Fan Y, Wysocki SJ, Lau AT, Robertson T, Beilharz M, Wood DJ, Papadimitriou JM: Gene expression of transforming growth factor- - 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration. Am J Pathol 1994; 145: 1095-1104.
14. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci USA 1998; 95: 3597-3602.
15. McNally AK, Anderson JM: Interleukin-4 induces foreign body giant cells from human monocytes/macrophages. Differential lymphokine regulation of macrophage fusion leads to morphological variants of multinucleated giant cells. Am J Pathol 1995; 147: 1487-1499.
16. DeFife KM, Jenney CR, McNally AK, Colton E, Anderson JM: Interleukin-13 induces human monocyte/macrophage fusion and macrophage mannose receptor expression. J Immunol 1997; 158: 3385-3390.
17. Helming L, Winter J, Gordon S: The scavenger receptor CD36 plays a role in cytokineinduced macrophage fusion. J Cell Sci 2009; 122: 453-459.
18. Anderson JM: Multinucleated giant cells. Curr Opin Hematol 2000; 7: 40-47.
19. Reiss AB, Patel CA, Rahman MM, Chan ES, Hasneen K, Montesinos MC, Trachman JD, Cronstein BN: Interferon-impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/ macrophages. Med Sci Monit 2004; 10: BR420-BR425.
20. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT: Inflammatory and non-invasive vascular markers: The multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008; 199: 3-11.
21. Lietman SA, Yin L, Levine MA: SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochem Biophys Res Commun 2008; 371: 644-648.
22. Xu J, Wu HF, Ang ES, Yip K, Woloszyn M, Zheng MH, Tan, RX: NF-B modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 2009; 20: 7-17.
23. Lee FY, Kim DW, Karmin JA, Hong D, Chang SS, Fujisawa M, Takayanagi H, Bigliani LU, Blaine TA, Lee HJ: -Calpain regulates receptor activator of NF- B ligand (RANKL)- supported osteoclastogenesis via NF- B activation in RAW 264.7 cells. J Biol Chem 2005; 280: 29929-29936.
24. Teitelbaum SL, Ross FP: Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4: 638-649.
25. Hotokezaka H, Sakai E, Ohara N, Hotokezaka Y, Gonzales C, Matsuo K, Fujimura Y, Yoshida N, Nakayama K: Molecular analysis of RANKL-independent cell fusion of osteoclast- like cells induced by TNF- , lipopolysaccharide, or peptidoglycan. J Cell Biochem 2007; 101: 122-134.
26. Benoit M, Desnues B, Mege JL: Macrophage polarization in bacterial infections. J Immunol 2008; 181: 3733-3739.
27. Varin A, Gordon S: Alternative activation of macrophages: Immune function and cellular biology. Immunobiology 2009; in press.
28. Anderson JM, Rodriguez A, Chang DT: Foreign body reaction to biomaterials. Semin Immunol 2008; 20: 86-100.
29. Yagi M, Ninomiya K, Fujita N, Suzuki T, Iwasaki R, Morita K, Hosogane N, Matsuo K, Toyama Y, Suda T et al.: Induction of DCSTAMP by alternative activation and downstream signaling mechanisms. J Bone Miner Res 2007; 22: 992-1001.
30. Kim MS, Day CJ, Morrison NA: MCP-1 is induced by receptor activator of nuclear factor- - B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem 2005; 280: 16163-16169.
31. Low QE, Drugea IA, Duffner LA, Quinn DG, Cook DN, Rollins BJ, Kovacs EJ, DiPietro LA: Wound healing in MIP-1 - -/- and MCP- 1 -/- mice. Am J Pathol 2001; 159: 457-463.
32. Brown EJ, Frazier, WA: Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001; 11: 130-135.
33. Babic I, Schallhorn A, Lindberg FP, Jirik FR: SHPS-1 induces aggregation of Ba/F3 pro-B cells via an interaction with CD47. J Immunol 2000; 164: 3652-3658.
34. Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, Lindberg FP, Vignery A: CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 2000; 275: 37984-37992.
35. Harris ES, McIntyre TM, Prescott SM, Zimmerman GA: The leukocyte integrins. J Biol Chem 2000; 275: 23409-23412.
36. McNally AK, Anderson JM: - 1 and - 2 integrins mediate adhesion during macrophage fusion and multinucleated foreign body giant cell formation. Am J Pathol 2002; 160: 621-630.
37. McNally AK, Macewan SR, Anderson JM: - Subunit partners to - 1 and - 2 integrins during IL-4-induced foreign body giant cell formation. J Biomed Mater Res A 2007; 82: 568-574.
38. Rao H, Lu G, Kajiya H, Garcia-Palacios V, Kurihara N, Anderson J, Patrene K, Sheppard D, Blair HC, Windle JJ, et al.: - 9 - 1 : A novel osteoclast integrin that regulates osteoclast formation and function. J Bone Miner Res 2006; 21: 1657-1665.
39. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL: CD36 and macrophages in atherosclerosis. Cardiovasc Res 2007; 75: 468-477.
40. Lee, WY, Kubes P: Leukocyte adhesion in the liver: distinct adhesion paradigm from other organs. J Hepatol 2008; 48: 504-512.
41. Sterling H, Saginario C, Vignery A: CD44 occupancy prevents macrophage multinucleation. J Cell Biol 1998; 143: 837-847.
42. Cui, W, Ke JZ, Zhang Q, Ke HZ, Chalouni C, Vignery A: The intracellular domain of CD44 promotes the fusion of macrophages. Blood 2006; 107: 796-805.
43. Minas K, Liversidge J: Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit Rev Immunol 2006; 26: 213-230.
44. Cui, W, Cuartas E, Ke J, Zhang Q, Einarsson HB, Sedgwick JD, Li J, Vignery A: CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts. Proc Natl Acad Sci USA 2007; 104: 14436-14441.
45. Lee SH, Rho J, Jeong D, Sul JY, Kim T, Kim N, Kang JS, Miyamoto T, Suda T, Lee SK et al.: v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 2006; 12: 1403-1409.
46. Wu H, Xu G, Li YP: Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res 2009; 24: 871-885.
47. North RA: Molecular physiology of P2X receptors. Physiol Rev 2002; 82: 1013-1067.
48. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A: The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 1997; 272: 5482-5486.
49. Lemaire I, Falzoni S, Leduc N, Zhang B, Pellegatti P, Adinolfi E, Chiozzi P, Di VF: Involvement of the purinergic P2X 7 receptor in the formation of multinucleated giant cells. J Immunol 2006; 177: 7257-7265.
50. Suda N, Morita I, Kuroda T, Murota S: Participation of oxidative stress in the process of osteoclast differentiation. Biochim Biophys Acta 1993; 1157: 318-323.
51. Steinbeck MJ, Kim JK, Trudeau MJ, Hauschka PV, Karnovsky MJ: Involvement of hydrogen peroxide in the differentiation of clonal HD-11EM cells into osteoclast-like cells. J Cell Physiol 1998; 176: 574-587.
52. Kim H, Kim IY, Lee SY, Jeong D: Bimodal actions of reactive oxygen species in the differentiation and bone-resorbing functions of osteoclasts. FEBS Lett 2006; 580: 5661-5665.
53. Kyung TW, Lee JE, Shin HH, Choi HS: Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF- - by inhibiting activation of NF- - B. Exp Mol Med 2008; 40: 52-58.
54. Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N, Lee SY: A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 2005; 106: 852-859.
55. Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, Zeng, WS, Cheng BL, Luo SQ: Reactive oxygen species stimulates receptor activator of NF- - B ligand expression in osteoblast. J Biol Chem 2005; 280: 17497-17506.
56. Wang Y, Lebowitz D, Sun C, Thang H, Grynpas MD, Glogauer M: Identifying the relative contributions of Rac1 and Rac2 to osteoclastogenesis. J Bone Miner Res 2008; 23: 260-270.
57. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ: NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 2003; 23: 776-782.
58. Wang YH, Wang, WY, Liao JF, Chen CF, Hou YC, Liou KT, Chou YC, Tien JH, Shen YC: Prevention of macrophage adhesion molecule- 1 (Mac-1)-dependent neutrophil firm adhesion by taxifolin through impairment of protein kinase-dependent NADPH oxidase activation and antagonism of G protein-mediated calcium influx. Biochem Pharmacol 2004; 67: 2251-2262.
59. Forman HJ, Torres M: Reactive oxygen species and cell signaling: respiratory burst in macrophage signaling. Am J Respir Crit Care Med 2002; 166:S4-S8.
60. Clark RA, Valente AJ: Nuclear factor - B activation by NADPH oxidases. Mech Ageing Dev 2004; 125: 799-810.
61. Simons K, Toomre D: Lipid rafts and signal transduction. Mol Cell Biol 2002; 1: 31-39.
62. Ha H, Kwak HB, Lee SK, Na DS, Rudd CE, Lee ZH, Kim HH: Membrane rafts play a crucial role in receptor activator of nuclear factor - B signaling and osteoclast function. J Biol Chem 2003; 278: 18573-18580.
63. Ishii M, Iwai K, Koike M, Ohshima S, Kudo- Tanaka E, Ishii T, Mima T, Katada Y, Miyatake K, Uchiyama Y, et al.: RANKL-induced expression of tetraspanin CD9 in lipid raft membrane microdomain is essential for cell fusion during osteoclastogenesis. J Bone Miner Res 2006; 21: 965-976.
64. Vilhardt F, Van Deurs B: The phagocyte NADPH oxidase depends on cholesterol-enriched membrane microdomains for assembly. EMBO J 2004; 23: 739-748.
65. Lu SP, Lin Feng MH, Huang HL, Huang YC, Tsou, WI, Lai MZ: Reactive oxygen species promote raft formation in T lymphocytes. Free Radic Biol Med 2007; 42: 936-944.
66. Quinn MT, Ammons MC, DeLeo FR: The expanding role of NADPH oxidases in health and disease: no longer just agents of death and destruction. Clin Sci 2006; 111: 1-20.
67. Steinbeck MJ, Appel, WH Jr, Verhoeven AJ, Karnovsky MJ: NADPH-oxidase expression and in situ production of superoxide by osteoclasts actively resorbing bone. J Cell Biol 1994; 126: 765-772.
68. Darden AG, Ries, WL, Wolf, WC, Rodriguiz RM, Key LL Jr: Osteoclastic superoxide production and bone resorption: stimulation and inhibition by modulators of NADPH oxidase. J Bone Miner Res 1996; 11: 671-675.
69. Kreipe H, Radzun HJ, Rudolph P, Barth J, Hansmann ML, Heidorn K, Parwaresch MR: Multinucleated giant cells generated in vitro. Terminally differentiated macrophages with down-regulated c-fms expression. Am J Pathol 1988; 130: 232-243.
70. Rittner HL, Kaiser M, Brack A, Szweda LI, Goronzy JJ, Weyand CM: Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999; 84: 1050-1058. (Pubitemid 29227684)
71. Lay G, Poquet Y, Salek-Peyron P, Puissegur MP, Botanch C, Bon H, Levillain F, Duteyrat JL, Emile JF, Altare F: Langhans giant cells from M. tuberculosis -induced human granulomas cannot mediate mycobacterial uptake. J Pathol 2007; 211: 76-85.
72. Yang S, Ries WL, Key LL Jr: Nicotinamide adenine dinucleotide phosphate oxidase in the formation of superoxide in osteoclasts. Calcif Tissue Int 1998; 63: 346-350.
73. Yang S, Madyastha P, Bingel S, Ries W, Key L: A new superoxide-generating oxidase in murine osteoclasts. J Biol Chem 2001; 276: 5452-5458.
74. Yang S, Zhang YZ, Ries W, Key L: Expression of Nox4 in osteoclasts. J Cell Biochem 2004; 92: 238-248.
75. Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J Jr, Pomerantzeff PM, Laurindo FR: Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 2008; 28: 463-470.
76. Sumimoto H: Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008; 275: 3249-3277.
77. Kawahara T, Quinn MT, Lambeth JD: Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. BMC Evolut Biol 2007; 7.
78. Cathcart MK, McNally AK, Morel DW, Chisolm GM III: Superoxide anion participation in human monocyte-mediated oxidation of low-density lipoprotein and conversion of low-density lipoprotein to a cytotoxin. J Immunol 1989; 142: 1963-1969.
79. Dewald B, Payne TG, Baggiolini M: Activation of NADPH oxidase of human neutrophils. Potentiation of chemotactic peptide by a diacylglycerol. Biochem Biophys Res Commun 1984; 125: 367-373.
80. Carlyon JA, Latif DA, Pypaert M, Lacy P, Fikrig E: Anaplasma phagocytophilum utilizes multiple host evasion mechanisms to thwart NADPH oxidase-mediated killing during neutrophil infection. Infect Immun 2004; 72: 4772-4783.
81. Cathcart MK: Regulation of superoxide anion production by NADPH oxidase in monocytes/ macrophages - contributions to atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 23-28.
82. Gabay C: Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8(suppl 2): S3.
83. Gauss KA, Nelson-Overton LK, Siemsen DW, Gao Y, DeLeo FR, Quinn MT: Role of NF- - B in transcriptional regulation of the phagocyte NADPH oxidase by tumor necrosis factor- - . J Leukoc Biol 2007; 82: 729-741.
84. Key LL Jr, Ries WL, Taylor RG, Hays BD, Pitzer BL: Oxygen derived free radicals in osteoclasts: The specificity and location of the nitroblue tetrazolium reaction. Bone 1990; 11: 115-119.
85. Ries, WL, Key LL Jr, Rodriguiz RM: Nitroblue tetrazolium reduction and bone resorption by osteoclasts in vitro inhibited by a manganese-based superoxide dismutase mimic. J Bone Miner Res 1992; 7: 931-939.
86. Martyn KD, Frederick LM, von Löhneysen K, Dinauer MC, Knaus UG: Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 2006; 18: 69-82.
87. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR: Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990; 85: 632-639.
88. Mochizuki T, Furuta S, Mitsushita J, Shang, W, Ito M, Yokoo Y, Yamaura M, Ishizone S, Nakayama J, Konagai A, et al.: Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 2006; 25: 3699-3707.
89. Segal BH, Romani L, Puccetti P: Chronic granulomatous disease. Cell Mol Life Sci 2009; 66: 553-558.
90. Dennis CG, Greco, WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, et al.: Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47 phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50: 422-427.
91. Arimura Y, Goto A, Yamashita K, Endo T, Ikeda H, Tanaka K, Tsutsumi H, Shinomura Y, Imai K: Intractable colitis associated with chronic granulomatous disease. J Med Microbiol 2006; 55: 1587-1590.
92. Malech HL, Hickstein DD: Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol 2007; 14: 29-36.
93. Kobayashi SD, Voyich JM, Braughton KR, Whitney AR, Nauseef, WM, Malech HL, De- Leo FR: Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. J Immunol 2004; 172: 636-643.
94. Baniulis D, Nakano Y, Nauseef, WM, Banfi B, Cheng G, Lambeth DJ, Burritt JB, Taylor RM, Jesaitis AJ: Evaluation of two anti-gp- 91phox antibodies as immunoprobes for Nox family proteins: MAb 54.1 recognizes recombinant full-length Nox2, Nox3 and the C-terminal domains of Nox1-4 and crossreacts with GRP 58. Biochim Biophys Acta 2005; 1752: 186-196.
95. Segal BH, Sakamoto N, Patel M, Maemura K, Klein AS, Holland SM, Bulkley GB: Xanthine oxidase contributes to host defense against Burkholderia cepacia in the p47 phox- /- mouse model of chronic granulomatous disease. Infect Immun 2000; 68: 2374-2378.
96. Mizuno K, Okamoto H, Horio T: Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors. Br J Dermatol 2004; 150: 205-210.
97. Hewinson J, Moore SF, Glover C, Watts AG, MacKenzie AB: A key role for redox signaling in rapid P2X7 receptor-induced IL-1 - processing in human monocytes. J Immunol 2008; 180: 8410-8420.
98. Alblas J, Honing H, de Lavalette CR, Brown MH, Dijkstra CD, van den Berg TK: Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NADPH oxidase/ H 2 O 2 -dependent pathways. Mol Cell Biol 2005; 25: 7181-7192.
99. Kim Y, Lee YS, Choe J, Lee H, Kim YM, Jeoung D: CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 2008; 283: 22513-22528.
100. Halleen JM, Räisänen SR, Alatalo SL, Väänänen HK: Potential function for the ROSgenerating activity of TRACP. J Bone Miner Res 2003; 18: 1908-1911.
101. Halleen JM, Räisänen SR, Salo JJ, Reddy SV, Roodman GD, Hentunen TA, Lehenkari PP, Kaija H, Vihko P, Väänänen HK: Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999; 274: 22907-22910.
102. Räisänen SR, Alatalo SL, Ylipahkala H, Halleen JM, Cassady AI, Hume DA, Väänänen HK: Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun 2005; 331: 120-126.
103. Seitzer U, Scheel-Toellner D, Toellner KM, Reiling N, Haas H, Galle J, Flad HD, Gerdes J: Properties of multinucleated giant cells in a new in vitro model for human granuloma formation. J Pathol 1997; 182: 99-105.
104. Vignery A: Macrophage fusion: Are somatic and cancer cells possible partners? Trends Cell Biol 2005; 15: 188-193.
105. Adams DO: The granulomatous inflammatory response. A review. Am J Pathol 1976; 84: 164-192.
106. Epstein WL, Fukuyama K: Mechanisms of granulomatous inflammation. Immunol Ser 1989; 46: 687-721.
107. Akritidis N, Tzivras M, Delladetsima I, Stefanaki S, Moutsopoulos HM, Pappas G: The liver in brucellosis. Clin Gastroenterol Hepatol 2007; 5: 1109-1112.
108. Jain V, Dabir S, Shome D, Dadu T, Natarajan S: Aspergillus iris granuloma: A case report with review of literature. Surv Ophthalmol 2009; 54: 286-291.
109. Shibuya K, Hirata A, Omuta J, Sugamata M, Katori S, Saito N, Murata N, Morita A, Takahashi K, Hasegawa C, et al.: Granuloma and cryptococcosis. J Infect Chemother 2005; 11: 115-122.
110. Lockwood DN, Lucas SB, Desikan KV, Ebenezer G, Suneetha S, Nicholls P: The histological diagnosis of leprosy type 1 reactions: Identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol 2008; 61: 595-600.
111. Hogan LH, Markofski, W, Bock A, Barger B, Morrissey JD, Sandor M: Mycobacterium bovis BCG-induced granuloma formation depends on - interferon and CD40 ligand but does not require CD28. Infect Immun 2001; 69: 2596-2603.
112. Byrd TF: Multinucleated giant cell formation induced by IFN- - /IL-3 is associated with restriction of virulent Mycobacterium tuberculosis cell to cell invasion in human monocyte monolayers. Cell Immunol 1998; 188: 89-96.
113. Saunders BM, Cooper AM: Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol Cell Biol 2000; 78: 334-341.
114. Rodriguez A, Macewan SR, Meyerson H, Kirk JT, Anderson JM: The foreign body reaction in T-cell-deficient mice. J Biomed Mater Res A 2008.
115. Mizuno K, Okamoto H, Horio T: Muramyl dipeptide and mononuclear cell supernatant induce Langhans-type cells from human monocytes. J Leukoc Biol 2001; 70: 386-394.
116. Okamoto H, Mizuno K, Horio T: Monocyte- derived multinucleated giant cells and sarcoidosis. J Dermatol Sci 2003; 31: 119-128.
117. Pereira-Suárez AL, Estrada-Chavez C, Arriaga- Diaz C, Espinosa-Cueto P, Mancilla R: Coexpression of NRAMP1, iNOS, and nitrotyrosine in bovine tuberculosis. Vet Pathol 2006; 43: 709-717.
118. Damle A, Mahadevan PR: In vivo effect of delipidified cell component of Mycobacterium leprae in relation to infection with leprosy bacteria in mice. Indian J Lepr 1993; 65: 271-282.
119. Pham NK, Mouriz J, Kima PE: Leishmania pifanoi amastigotes avoid macrophage production of superoxide by inducing heme degradation. Infect Immun 2005; 73: 8322-8333.
120. Bylund J, Goldblatt D, Speert DP: Chronic granulomatous disease: from genetic defect to clinical presentation. Adv Exp Med Biol 2005; 568: 67-87.
121. Kottilil S, Malech HL, Gill VJ, Holland SM: Infections with Haemophilus species in chronic granulomatous disease: Insights into the interaction of bacterial catalase and H 2 O 2 production. Clin Immunol 2003; 106: 226-230.
122. Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT: Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease - evidence against enhanced neutrophil oxidase activity. Blood 1992; 79: 1558-1562.
123. Black MM, Epstein, WL: Formation of multinucleate giant cells in organized epitheloid cell granulomas. Am J Pathol 1974; 74: 263-274.
124. Anderson JM, Jones JA: Phenotypic dichotomies in the foreign body reaction. Biomaterials 2007; 28: 5114-5120.
125. Moreno JL, Mikhailenko I, Tondravi MM, Keegan AD: IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin. J Leukoc Biol 2007; 82: 1542-1553.
126. McNally AK, Jones JA, Macewan SR, Colton E, Anderson JM: Vitronectin is a critical protein adhesion substrate for IL-4-induced foreign body giant cell formation. J Biomed Mater Res A 2008; 86: 535-543.
127. Wang ML, Hauschka PV, Tuan RS, Steinbeck MJ: Exposure to particles stimulates superoxide production by human THP-1 macrophages and avian HD-11EM osteoclasts activated by tumor necrosis factor- - and PMA. J Arthroplasty 2002; 17: 335-346.
128. Gristina AG: Implant failure and the immuno- incompetent fibro-inflammatory zone. Clin Orthop Relat Res 1994; 106-118.
129. Lee KH, Chu CC: The role of superoxide ions in the degradation of synthetic absorbable sutures. J Biomed Mater Res 2000; 49: 25-35.
130. Schubert MA, Wiggins MJ, Anderson JM, Hiltner A: Comparison of two antioxidants for poly(etherurethane urea) in an accelerated in vitro biodegradation system. J Biomed Mater Res 1997; 34: 493-505.
131. Udipi K, Ornberg RL, Thurmond KB, Settle SL, Forster D, Riley D: Modification of inflammatory response to implanted biomedical materials in vivo by surface bound superoxide dismutase mimics. J Biomed Mater Res 2000; 51: 549-560.
132. Suzuki R, Muyco J, McKittrick J, Frangos JA: Reactive oxygen species inhibited by titanium oxide coatings. J Biomed Mater Res A 2003; 66: 396-402.
133. Ward B, Anderson J, McVenes R, Stokes K: In vivo biostability of polyether polyurethanes with fluoropolymer surface modifying endgroups: resistance to biologic oxidation and stress cracking. J Biomed Mater Res A 2006; 79: 827-835. (Pubitemid 44915903)
134. Torralba KD, Quismorio FP Jr: Sarcoidosis and the rheumatologist. Curr Opin Rheumatol 2009; 21: 62-70.
135. Spector, WG: Immunologic components of granuloma formation. Epithelioid cells, giant cells, and sarcoidosis. Ann N Y Acad Sci 1976; 278: 3-6.
136. Singh M, Kothur K: Pulmonary sarcoidosis masquerading as tuberculosis. Indian Pediatr 2007; 44: 615-617.
137. Papaetis GS, Pefanis A, Solomon S, Tsangarakis I, Orphanidou D, Achimastos A: Asymptomatic stage I sarcoidosis complicated by pulmonary tuberculosis: A case report. J Med Case Reports 2008; 2: 226.
138. Schaberg T, Rau M, Stephan H, Lode H: Increased number of alveolar macrophages expressing surface molecules of the CD11/ CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells. Am Rev Respir Dis 1993; 147: 1507-1513.
139. Wilkinson LS, Pitsillides AA, Edwards JC: Giant cells in arthritic synovium. Ann Rheum Dis 1993; 52: 182-184.
140. Weinberg JB, Wortham TS, Misukonis MA, Patton KL, Chitneni SR: Synovial mononuclear phagocytes in rheumatoid arthritis and osteoarthritis: quantitative and functional aspects. Immunol Invest 1993; 22: 365-374.
141. Takano H, Tomita T, Toyosaki-Maeda T, Maeda-Tanimura M, Tsuboi H, Takeuchi E, Kaneko M, Shi K, Takahi K, Myoui A, et al.: Comparison of the activities of multinucleated bone-resorbing giant cells derived from CD14-positive cells in the synovial fluids of rheumatoid arthritis and osteoarthritis patients. Rheumatology (Oxford) 2004; 43: 435-441.
142. Ainola M, Mandelin J, Liljestrom M, Konttinen YT, Salo J: Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 240-246.
143. Miesel R, Hartung R, Kroeger H: Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseases. Inflammation 1996; 20: 427-438
144. 't Hart BA, Simons JM, Knaan-Shanzer S, Bakker NPM, LaBadie RP: Antiarthritic activity of the newly developed neutrophil oxidative burst antagonist apocynin. Free Radic Biol Med 1990; 9: 127-131.
145. Cronstein BN, Eberle MA, Gruber HE, Levin RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88: 2441-2445.
146. Miesel R, Kurpisz M, Kröger H: Suppression of inflammatory arthritis by simultaneous inhibition of nitric oxide synthase and NADPH oxidase. Free Radic Biol Med 1996; 20: 75-81.
147. Van de Loo, FAJ, Bennink MB, Arntz OJ, Smeets RL, Lubberts E, Joosten LAB, van Lent PLEM, Coenen-de Roo CJJ, Cuzzocrea S, Segal BH, et al.: Deficiency of NADPH oxidase components p47phox and gp91 phox caused granulomatous synovitis and increased connective tissue destruction in experimental arthritis models. Am J Pathol 2003; 163: 1525-1537.
148. Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl R: Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat Genet 2003; 33: 25-32.
149. Hultqvist M, Olofsson P, Holmberg J, Backstrom BT, Tordsson J, Holmdahl R: Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene. Proc Natl Acad Sci USA 2004; 101: 12646-12651.
150. Bryant PA, Robins-Browne R, Carapetis JR, Curtis N: Some of the people, some of the time: susceptibility to acute rheumatic fever. Circulation 2009; 119: 742-753.
151. Ferrans VJ, Rodriguez ER, McAllister HA Jr: Granulomatous inflammation of the heart. Heart Vessels Suppl 1985; 1: 262-270.
152. Fraser, WJ, Haffejee Z, Cooper K: Rheumatic Aschoff nodules revisited: An immunohistological reappraisal of the cellular component. Histopathology 1995; 27: 457-461.
153. Fraser, WJ, Haffejee Z, Jankelow D, Wadee A, Cooper K: Rheumatic Aschoff nodules revisited. II: cytokine expression corroborates recently proposed sequential stages. Histopathology 1997; 31: 460-464.
154. Kawasaki A, Purvin V: Giant cell arteritis: An updated review. Acta Ophthalmol 2009; 87: 13-32.
155. Weyand CM, Goronzy JJ: Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 2003; 139: 505-515.
156. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM: Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997; 3: 530-543.
157. Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M: Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008; 44: 207-220.
158. Nordborg E, Bengtsson BA, Petursdottir V, Nordborg C: Morphological aspects of giant cells in giant cell arteritis: An electronmicroscopic and immunocytochemical study. Clin Exp Rheumatol 1997; 15: 129-134.
159. Nordborg E, Nordborg C: Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology 2003; 42: 413-421.
160. Ma-Krupa, W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM: Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173-183.
161. Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, et al.: Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med 2008; 14: 81-87.
162. Ma-Krupa, W, Dewan M, Jeon MS, Kurtin PJ, Younge BR, Goronzy JJ, Weyand CM: Trapping of misdirected dendritic cells in the granulomatous lesions of giant cell arteritis. Am J Pathol 2002; 161: 1815-1823.
163. Weyand CM, Goronzy JJ: Pathogenic mechanisms in giant cell arteritis. Cleve Clin J Med 2002; 69(suppl 2):SII28-SII32.
164. Shionoya S, Tsunekawa S, Kamiya K: Elastolysis and giant cell reaction against disintegrated elastic fibres. Nature 1965; 207: 311-312.
165. Gillot JM, Masy E, Davril M, Hachulla E, Hatron PY, Devulder B, Dessaint JP: Elastase derived elastin peptides: putative autoimmune targets in giant cell arteritis. J Rheumatol 1997; 24: 677-682.
166. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H, Lord RSA, Geczy CL: S100A8 and S100A9 in human arterial wall - Implications for atherogenesis. J Biol Chem 2005; 280: 41521-41529.
167. Hessian PA, Edgeworth J, Hogg N: MRP-8 and MRP-14, two abundant Ca 2+ -binding proteins of neutrophils and monocytes. J Leukoc Biol 1993; 53: 197-204.
168. Kerkhoff C, Nacken, W, Benedyk M, Dagher MC, Sopalla C, Doussiere J: The arachidonic acid-binding protein S100A8/A9 promotes NADPH oxidase activation by interaction with p67 phox and Rac-2. FASEB J 2005; 19: 467-469.
169. Borkowski A, Younge BR, Szweda L, Mock B, Bjornsson J, Moeller K, Goronzy JJ, Weyand CM: Reactive nitrogen intermediates in giant cell arteritis: selective nitration of neocapillaries. Am J Pathol 2002; 161: 115-123.
170. Goldring SR, Roelke MS, Petrison KK, Bhan AK: Human giant cell tumors of bone identification and characterization of cell types. J Clin Invest 1987; 79: 483-491.
171. Zheng MH, Robbins P, Xu J, Huang L, Wood DJ, Papadimitriou JM: The histogenesis of giant cell tumour of bone: A model of interaction between neoplastic cells and osteoclasts. Histol Histopathol 2001; 16: 297-307.
172. Roessner A, von Bassewitz DB, Schlake, W, Thorwesten G, Grundmann E: Biologic characterization of human bone tumors. III. Giant cell tumor of bone. A combined electron microscopical, histochemical, and autoradiographical study. Pathol Res Pract 1984; 178: 431-440.
173. Ciplea AG, Metze K, Grundmann E, Roessner A, Hettwer H: Microphotometric quantitation of enzyme activities in giant cell tumor of bone. A case study. Pathol Res Pract 1985; 179: 412-418.
174. Metze K, Ciplea AG, Hettwer H, Barckhaus RH: Size dependent enzyme activities of multinucleated (osteoclastic) giant cells in bone tumors. Pathol Res Pract 1987; 182: 214-221.